Edgewise Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -590 | |||
EBITDA | -56,786 | -48,423 | -51,860 | -40,143 |
EBIT | -57,327 | -49,013 | -50,216 | -40,666 |
Net Income | -57,327 | -49,013 | -50,216 | -40,666 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -43,542 | -42,803 | -38,409 | -34,865 |
Cash | 72,319 | 33,211 | 61,148 | 46,003 |
Basic Shares | 107,669 | 107,116 | 102,930 | 105,492 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -2,266 | -2,290 | -1,732 | -538 |
EBITDA | -165,529 | -131,523 | -98,431 | -21,541 |
EBIT | -167,795 | -133,813 | -100,163 | -22,079 |
Net Income | -167,795 | -133,813 | -100,163 | -15,397 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 6,427 | |||
Free Cash Flow | -143,816 | -110,340 | -97,693 | -58,181 |
Cash | 61,148 | 41,666 | 86,097 | 21,993 |
Basic Shares | 102,930 | 92,414 | 63,723 | 53,593 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.53 |
2026-03-31 | -$0.46 |
2025-12-31 | -$0.47 |
2025-09-30 | -$0.39 |